Pharmacologic Drug Detection and Self-Reported Adherence in the HPTN069/ACTG5305 Phase II PrEP Trial

By sjmartinez • August 1, 2024

Cooper SE, Zhang S, Haines D, Mayer KH, Amico KR, Landovitz RJ, Hendrix CW, Marzinke MA, Chege W, McCauley M, Gulick RM. Pharmacologic Drug Detection and Self-Reported Adherence in the HPTN069/ACTG5305 Phase II PrEP Trial. AIDS Behav. 2024 Jul 31. doi: 10.1007/s10461-024-04451-7. Epub ahead of print. PMID: 39083151.

Tags: Adherence, CASI, HIV prevention, Infectious Diseases, Maraviroc, PrEP, Publications, Tenofovir

Informing estimates of probability of Clostridioides difficile infection for testing and treatment: expert consensus from a modified-Delphi procedure

Baghdadi JD, Wessel M, Dubberke ER, Lydecker A, Claeys KC, Alonso C, Coffey KC, Durkin M, Gonzales-Luna AJ, Guh AY, Kwon JH, Martin E, Mehrotra[...]

Viral and symptom rebound following anti-SARS-CoV-2 monoclonal antibody therapy in a randomized placebo-controlled trial

Chew KW, McGinley B, Moser C, Li JZ, Evering TH, Ritz J, Javan AC, Margolis D, Wohl DA, Hughes MD, Daar ES, Currier JS, Eron[...]

Time series analysis of comprehensive maternal deaths in Brazil during the COVID-19 pandemic

Cambou MC, David H, Moucheraud C, Nielsen-Saines K, Comulada WS, Macinko J. Time series analysis of comprehensive maternal deaths in Brazil during the COVID-19 pandemic.[...]